Azitra (NYSEAMERICAN:AZTR) Trading Down 5.1%

Shares of Azitra, Inc. (NYSEAMERICAN:AZTR) traded down 5.1% during mid-day trading on Thursday . The company traded as low as $0.18 and last traded at $0.19. 607,320 shares were traded during mid-day trading, an increase of 18% from the average session volume of 513,998 shares. The stock had previously closed at $0.20.

Azitra Stock Down 5.1 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.58 and a current ratio of 1.58.

Insider Transactions at Azitra

In other news, CEO Francisco D. Salva acquired 333,300 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average price of $0.30 per share, for a total transaction of $99,990.00. Following the completion of the acquisition, the chief executive officer now owns 338,300 shares in the company, valued at $101,490. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders bought 399,200 shares of company stock valued at $115,476.

Institutional Investors Weigh In On Azitra

Several hedge funds have recently added to or reduced their stakes in AZTR. Warberg Asset Management LLC raised its holdings in Azitra by 20.7% in the third quarter. Warberg Asset Management LLC now owns 35,000 shares of the company’s stock worth $52,000 after buying an additional 6,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Azitra during the second quarter valued at approximately $57,000. Finally, Knollwood Investment Advisory LLC bought a new stake in shares of Azitra during the third quarter valued at approximately $62,000. 11.16% of the stock is owned by institutional investors.

About Azitra

Azitra, Inc, a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.